Skip to main content
×
Login
Submit a Manuscript
Home
Journal
Current Issue
Archive
For Authors
Column Series
Research & Insight
Special Reports
Subscribe
Resources
Blogs
Expert Insights
Latest News
Pathways Beyond Oncology
Topics
Comparative Effectiveness Research
Cost-Effectiveness Research
COVID-19 Updates
Guideline Updates
Health Economics and Outcomes Research
Health Technology
Real-World Data
Reimbursement
Value-Based Care
Specialties
Acute Lymphoblastic Leukemia
Acute Myeloid Leukemia
B-Cell Lymphoma
Biosimilars
Bladder Cancer
Breast Cancer
CAR-T Therapies
Chronic Lymphocytic Leukemia
Chronic Myeloid Leukemia
Colorectal Cancer
Diffuse Large B-Cell Lymphoma
Follicular Lymphoma
Gastrointestinal Cancer
Genitourinary Cancer
Gynecologic Cancer
Head and Neck Cancer
Immuno-Oncology
Kidney Cancer
Liver Cancer
Lung Cancer
Mantle Cell Lymphoma
Melanoma
Multiple Myeloma
Non-Small Cell Lung Cancer
Ovarian Cancer
Pancreatic Cancer
Prostate Cancer
Skin Cancer
Supportive Care
Excellence Forums
Mantle Cell Lymphoma Excellence Forum
Conferences
Oncology Clinical Pathways Congress
ASCO Gastrointestinal Cancers Symposium
ACCC Annual Meeting & Cancer Center Business Summit
ASCO Genitourinary Cancers Symposium
ASH Annual Meeting and Exposition
Oncology CME
About
About Us
Contact
Ovarian Cancer
Featured
Quiz
Quiz: Cost-Effectiveness of Targeted Genetic Testing for Breast and Ovarian Cancer
True or False: Targeted BRCA or multiple gene screening is cost-effective to prevent breast and ovarian cancer.
News
Cost-Sharing Patterns for PARP Inhibitor Therapy in Ovarian Cancer
Results from a single-center study show payers incur the bulk of monthly PARP inhibitor cost for ovarian cancer.
News
Targeted Genetic Testing Cost-Effective for Breast and Ovarian Cancer
Targeted BRCA or multiple gene screening is cost-effective for preventing breast and ovarian cancer, according to a…
Quiz
Quiz: Rucaparib vs Chemotherapy for BRCA-Mutated Ovarian Cancer
True or False: Rucaparib improves PFS compared with chemotherapy in patients with relapsed BRCA-mutated ovarian cancer.
News
Total and Out-of-Pocket Costs of PARP Inhibitor Therapy for Ovarian Cancer
PARP inhibitor therapy costs account for over 90% of patients’ total out-of-pocket drug spending. However, payers are…
News
Cost-Sharing Patterns for PARP Inhibitor Therapy in Ovarian Cancer
Targeted Genetic Testing Cost-Effective for Breast and Ovarian Cancer
Total and Out-of-Pocket Costs of PARP Inhibitor Therapy for Ovarian Cancer
Cost-Effectiveness of Genomic Screening for Hereditary Breast and Ovarian Cancer
Guideline Updates
NCCN Releases Updated Treatment Guideline for Ovarian Cancer
Interviews
PARP Inhibitors in Front-Line and Maintenance Therapy of Ovarian Cancer: A Changing Standard of Care
Videos
PROs Comparable Between Niraparib, Placebo in Advanced Ovarian Cancer
Podcast
Ovarian Cancer Maintenance: PRIMA, PAOLA-1, VELIA, and Others
Conference Coverage
Olaparib Maintenance Demonstrates Long-Term PFS Benefit for Advanced Ovarian Cancer
Stay in the know.
Journal of Clinical Pathways Newsletter
Back to Top